EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy

Prema Robinson, Tan Hoang iD, Zara Italia iD, Zal Italia iD, Chia-Chi Chang, Ashish V Damania iD, Nadim J Ajami iD, Emma Rodriguez, Moses Kasembeli, Leticia Hamana Zorrilla iD, Luisa Maren Solis Soto iD, Caelyn Pham und 6 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Prema Robinson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine, University of Texas MD Anderson Cancer Center…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Colitis-Associated Neoplasms, Colitis, Colorectal Neoplasms. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) occurs with higher frequency in patients with inflammatory bowel disease (IBD) and has increased morbidity and mortality compared with CRC in patients in the general population. STAT3 has been implicated in CRC development, but strategies to target it have yet to be employed to prevent its occurrence in groups at high risk for CRC. Our group developed TTI-101, a small-molecule STAT3 inhibitor, which was effective in treating colitis in the dextran sodium sulfate (DSS) mouse model. In the current study, we examined the ability of TTI-101 to prevent CRC in the azoxymethane (AOM)-DSS mouse model of CRC. Mice received AOM followed by DSS and were treated with either TTI-101 or vehicle control for 10 weeks. While vehicle-treated AOM-DSS mice developed polyps and adenocarcinomas, TTI-101-treated AOM-DSS mice did not. Levels of activated STAT3 (pY-STAT3) were increased in both the epithelial and stromal compartments of adenocarcinomas vs. normal colon mucosa and correlated with adenocarcinoma burden. Pharmacologically relevant concentrations of TTI-101 were detected in plasma and colon; plasma levels correlated with colon levels and correlated inversely with adenocarcinoma number. Transcriptomic analyses revealed that TTI-101 normalized expression of AOM-DSS-induced CRC-associated genes in the colon, many of which are regulated by STAT3. The addition of DSS to AOM resulted in a distinct cecal microbiome diversity and composition that was muted by the addition of TTI-101. Thus, TTI-101 prevented colitis-associated CRC in the AOM-DSS model through targeting STAT3’s pro-oncogenic effects on the colon transcriptome and modulating colitis-associated dysbiosis; targeting STAT3 in patients with IBD merits consideration for CRC prevention, as well as IBD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorColitis-Associated NeoplasmsColitisColorectal NeoplasmsAnimalsMiceAzoxymethaneDextran SulfateDisease Models, AnimalMaleHumansMice, Inbred C57BL

Stichwörter der Autor:innen

anti-cancer STAT3 inhibitorcolorectal cancerinflammatory bowel diseaseprevention strategy

Substanzen

STAT3 Transcription FactorAzoxymethaneDextran SulfateStat3 protein, mouse

Autor:innen und Institutionen

  • Departments of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA.
  • Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Department of Translational Molecular Pathology, Division of Pathology of Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
  • Department of Biology, School of Arts and Sciences, University of St. Thomas, Houston, TX 77006, USA.
  • Department of Biology & Biochemistry, College of Natural Sciences and Mathematics, University of Houston, Houston, TX 77204, USA.
  • Department of Symptom Research, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

ORCID-Profile: Tan Hoang, Zara Italia, Zal Italia, Ashish V Damania, Nadim J Ajami, Leticia Hamana Zorrilla, Luisa Maren Solis Soto, Uddalak Bharadwaj, David J Tweardy

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH/NCI

Zitieren

APA

Robinson, P., Hoang, T., Italia, Z., Italia, Z., Chang, C. C., Damania, A. V., Ajami, N. J., Rodriguez, E., Kasembeli, M., Zorrilla, L. H., Soto, L. M. S., Pham, C., Nguyen, J., Zamil, Y., Durán, C. A. C., Bharadwaj, U., Mahalingam, R., & Tweardy, D. J. (2026). Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188381

Vancouver

Robinson P, Hoang T, Italia Z, Italia Z, Chang CC, Damania AV, et al. Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188381

BibTeX
@article{Robinson2026,
  author = {Robinson, Prema and Hoang, Tan and Italia, Zara and Italia, Zal and Chang, Chia-Chi and Damania, Ashish V and Ajami, Nadim J and Rodriguez, Emma and Kasembeli, Moses and Zorrilla, Leticia Hamana and Soto, Luisa Maren Solis and Pham, Caelyn and Nguyen, Jacob and Zamil, Yousef and Durán, César Andrés Chávez and Bharadwaj, Uddalak and Mahalingam, Rajasekaran and Tweardy, David J},
  title = {Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188381}
}
Kostenlos starten →